Assessment and treatment selection for 'revolving door' inpatients with schizophrenia

Psychiatric Quarterly

Volumn 68, Issue 4, 1997, Pages 377-392

  Weiden, Peter ^a   Glazer, William ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; CONFERENCE PAPER; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RELAPSE; SCHIZOIDISM; SCHIZOPHRENIA; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; RECURRENCE; SCHIZOPHRENIA;

EID: 0030727332     PISSN: 00332720     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025499131905     Document Type: Conference Paper

References (19)

1. Weiden P, Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin. 1995;21:419-428.
2. Redick RW, Witkin MJ, Atay JE, Manderscheid RW. Availability of psychiatric beds, United States: Selected years, 1970-1990. DHHS Publication No. (SMA) 94-3001. 1994;213:1-7.
3. Dickey B, Normand S-L, Norton E, Azeni H, Fisher W, Altaffer F. Managing the care of schizophrenia: Lessons from the 4-year Massachusetts Medicaid study. Archives of General Psychiatry. 1996;53:945-952.
4. Witkin M, Atay J, Manderscheid R. Trends in state and county mental hospitals in the U.S. from 1970 to 1992. Psychiatric Services. 1996;47:1079-1081.
5. Essock S. Clozapine's effectiveness: Results of a 2-year randomized trial. NCDEU. Boca Raton, FL; 1996.
6. Glazer W, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Journal of Clinical Psychiatry. 1996;57:337-345.
7. Glazer W, Kane J. Depot neuroleptic therapy: An underutilized treatment option. J. Clin. Psychiatry. 1992;53:426-433.
8. Johnson DAW. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry. 1979;135:524-530.
9. Kissling W. The current unsatisfactory state of relapse prevention in schizophrenic psychoses - suggestions for improvement. Clinical Neuropharmacology. 1991;14:33-44.
10. Munk-Jorgensen P, Lutzhoft JH, Jensen J, Stromgren E. Trends in psychiatric hospitalization in Denmark: A 10-year register-based investigation. Acta Psychiatrica Scandinavica. 1992;86:79-83.
11. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry. 1996;57:53-60.
12. Weiden P. Using atypical antipsychotics. Journal of Practical Psychiatry and Behavioral Health. 1995;1:115-119.
13. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: A case-control study of seriously mentally ill persons in Mississippi. American Journal of Psychiatry. 1995;152:1749-1756.
14. Nageotte C, Sullivan G, Duan N, Camp P. Medication compliance among the seriously mentally ill in a public mental health system. Social Psychiatry and Psychiatric Epidemiology. 1997;32:49-56.
15. Mechanic D, Surles R. Challenges in state mental health policy and administration. Health Affairs 1992:34-50.
16. Weiden P, Olfson M, Essock S. Medication Noncompliance and Mental Health Policy. In: Blackwell B, ed. Compliance and the Treatment Alliance; 1996:35-60.
17. Kessler R, McGonagle K, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry. 1994;51:8-19.
18. McEvoy J, Weiden P, Smith T, Carpenter D, Kahn D, Frances A. The Expert Consensus Guideline Series: Treatment of Schizophrenia. Journal of Clinical Psychiatry. 1996;(Suppl 12B).
19. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman A, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot regimen. Psychiatric Services. 1995;46:1049-1054.